市場調查報告書

GSK3228836:新藥的考察與市場預測 (2030年)

GSK3228836- Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 968218
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
GSK3228836:新藥的考察與市場預測 (2030年) GSK3228836- Emerging Drug Insight and Market Forecast - 2030
出版日期: 2020年10月31日內容資訊: 英文 50 Pages
簡介

本報告提供現在臨床實驗中的慢性B型肝炎的治療藥 (反義寡核苷酸 (ASO)) 的GSK3228836市場結構、趨勢相關分析,產品概要 (用法、容量,作用機制等) 和相關法規,產品開發、臨床實驗的進展, 主要7個國家(美國,歐洲5個國家 (德國,法國,義大利,西班牙,英國),日本)的市場規模趨勢預測 (2020∼2030年),市場競爭狀態、SWOT分析,其他治療藥的競爭狀態,資本交易的動向,今後的市場成長可能性等調查、考察。

目錄

第1章 醫藥品概要

  • 產品的詳細資訊
  • 作用機制
  • 用法、用量
  • 研究開發 (R&D) 活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家 (7MM)的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場參與企業

第6章 其他新治療方法

第7章 附錄

第8章 報告購買選擇

目錄
Product Code: DIDM0073

"GSK3228836- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Hepatitis B in 7 Major Markets. A detailed picture of the GSK3228836 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

GSK3228836 is an investigational antisense oligonucleotide (ASO) that has been designed to specifically recognise the messenger RNA (mRNA) that the Hepatitis B virus uses to make viral antigens (disease-causing protein) in infected cells (hepatocytes) in the liver. It helps to destroy the mRNA by recruiting the liver's own enzymes to digest it to an inactive form. The subsequent reduction in the levels of the mRNA results in a decrease in the production of viral antigen (HBsAg) by the hepatocytes, which can be measured by a drop in the antigen levels in the circulating blood. GSK3228836 (previously known as 'ISIS 505358 or IONIS-HBVRX') was discovered by and jointly developed with Ionis Pharmaceuticals. GSK3228836 is one of the ASO HBV programme assets in-licensed by GSK from Ionis Pharmaceuticals in August 2019. GSK is now fully responsible for all development, regulatory and commercialisation activities and costs.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around GSK3228836.
  • The report contains forecasted sales for GSK3228836 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Hepatitis B.
  • The report also features the SWOT analysis with analyst insights and key findings of GSK3228836.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GSK3228836 Analytical Perspective by DelveInsight

  • In-depth GSK3228836 Market Assessment

This report provides a detailed market assessment of GSK3228836 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • GSK3228836 Clinical Assessment

The report provides the clinical trials information of GSK3228836 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence GSK3228836 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Hepatitis B are giving market competition to GSK3228836 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of GSK3228836.
  • Our in-depth analysis of the forecasted sales data of GSK3228836 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GSK3228836.

Key Questions:

  • Which company is developing GSK3228836 along with the phase of the clinical study?
  • What is the technology utilized in the development of GSK3228836?
  • What is the product type, route of administration and mechanism of action of GSK3228836?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GSK3228836 development?
  • What are the key designations that have been granted to GSK3228836?
  • What is the forecasted market scenario of GSK3228836?
  • What is the history of GSK3228836 and what is its future?
  • What is the forecasted sales of GSK3228836 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to GSK3228836?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 GSK3228836, Description
  • Table 2 GSK3228836, Clinical Trial Description
  • Table 3 GSK3228836, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of GSK3228836
  • Figure 2 Patent Details, GSK3228836
  • Figure 3 GSK3228836, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 GSK3228836, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 GSK3228836, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 GSK3228836, Japan Market Size from 2020 to 2030 (in Millions USD)